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Methods: Patients in a randomized phase III study conducted in 
western patients (Study-W1) received PEM 500mgm2 or 900mg/m2 
once every 3 weeks. Patients enrolled in a randomized phase II study 
conducted in Japan (Study-J1) received PEM 500mg/m2 or 1000mg/
m2 once every 3 weeks. Eligible patients in each of the studies had a 
histologic or cytologic diagnosis of NSCLC and had been previously 
treated. An established pharmacokinetic model was used to estimate 
AUCs from CrCL for patients in Study-W0 that received PEM 500mg/
m2 (N=265) and for patients in Study-J1. AUC was evaluated as a pre-
dictor of clinical efﬁcacy (survival, TTPD, PFS) to identify ERRs. The 
models included previously identiﬁed prognostic factors and inverse of 
mean daily AUC over the treatment period as covariates.
Results: Study-W1 did not show a survival advantage for the 900mg/
m2 (N=293) dose over the 500mg/m2 (N=295) dose. Study-J1 showed 
PEM 500mg/m2 (N=108) and 1000mg/m2 (N=108) to have similar 
efﬁcacy for Japanese patients with previously treated NSCLC. Of 
the efﬁcacy ERRs evaluated for Study-W0 and Study-J1, AUC was 
independently signiﬁcant only for TTPD in Study-W0 and was not 
signiﬁcant for other ERRs in either study (ERRs were not evaluated for 
Study-W1). There is internal consistency between the Study-J1 clinical 
results and the lack of ERRs for that study and external consistency 
between the Study-W1 clinical results and the lack of survival ERR for 
Study-W0.
Conclusion: Based on results available from two large randomized 
clinical trials and the evaluation of exposure-response relationships 
from a third trial, high dose PEM (900mg/mm2 or 1000mg/m2) does not 
offer an efﬁcacy advantage over the currently approved 500mg/m2 dose 
for either western or Japanese patient populations.
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Background: Optimal treatment for elderly patients with NSCLC has 
been under active investigation. This study evaluated the safety and 
initial efﬁcacy of a novel combination regimen of oral ﬂuoropyrimidine 
TS-1 plus gemcitabine (GEM) for elderly patients (pts) with advanced 
NSCLC.
Methods: A phase I/II trial in 11 centers examined TS-1 and GEM 
in pts with age ≥ 70, stage IIIB/IV previously untreated NSCLC. The 
starting dose was 60 mg/day (day 1-14) for TS-1 and 800 mg/m2 for 
GEM (day 8, 15). GEM was increased to 1000 mg/m2 at dose level 2 
and TS-1 was increased to 80 mg/day at dose level 3. Phase II portion 
of the study assessed the efﬁcacy and tolerability of the combination 
regimen at the dose determined in the phase I portion. The primary 
endpoint was objective response rate.
Results: Twenty two pts were enrolled in the phase I portion: 6 pts on 
dose level 1, 10 on dose level 2 and 6 on dose level 3. Median age of 
this group was 75 yrs (range 70-85). Dose limiting toxicities included 
Gr. 4 neutropenia (2 pts) and Gr.3 skin toxicity (4 pts). The recom-
mended dose (RD) was TS-1 60 mg/day and GEM 1000 mg/m2, with 
which 20 pts were subsequently treated in the phase II portion. The me-
dian age of 30 pts treated with the RD was 76 yrs (range 70-85). Grade 
(Gr) 3/4 toxicities include neutropenia (12 pts; 7 with Gr 4), thrombo-
cytopenia (4 pts; 0 with Gr 4), skin toxicity (8 pts), thrombus (1 pt) and 
peumonitis (2 pts). Nine patients (30%, 95% conﬁdence interval [CI] 
= 14 to 46%) had partial responses and 16 (53%, 95% CI = 35 to 71%) 
had stable disease. 
Conclusion: Encouraging antitumor activity and safety of TS-1 plus 
gemcitabine support further development of this combination therapy 
for elderly patients with advanced NSCLC.
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Background: Carboplatin AUC 5 d1-Gemcitabine 1250 mg/m2 d1, 8 
is an approved standard regimen in advanced NSCLC. Hematologic 
toxicity is however frequent; thrombocytopenia is found in more than 
40 % of cases, neutropenia in 20%.
Aim: to investigate in two equally dose-dense regimens, whether the 
toxicity of the Gemcitabine-Carboplatin combination could be reduced 
by administering Carboplatin on day 8 instead of day 1 and without 
change in response rate.
Methods: Patients in arm A are treated with Gemcitabine (1250 mg/m2 
days 1,8) and Carboplatin (AUC 5 day 1) Patients in arm B are treated 
with Gemcitabine (1250 mg/m2 days 1,8) and Carboplatin (AUC 5 day 
8. ) Drugs are administered over a 21-day cycle, on an outpatient basis. 
Toxicity and response are evaluated weekly and every second cycle, 
respectively. 
Statistics: The hypothesis of the study protocol is that regimen B 
shows a decrease in toxicity of 50% without loss of response rates. 
Toxicity is deﬁned as a thrombocytopenia and/or neutropenia grade ı. 
The Bryan and Day design allows to consider both response and toxic-
ity as primary endpoint. With an alpha of 0.10 and a power of 90% the 
sample size was estimated to be 67 patients in each arm. An interim 
analysis was performed after 54 included patients, 27 in each arm. 
Results: A total of 71 patients were enrolled between April 2004 and 
March 2006, before the study was prematurely stopped because data 
showed a statistical signiﬁcant difference in toxicity. Patient and dis-
ease characteristics for the 69 eligible patients are summarized in Table 
1. Toxicity and response are reported in Table 2.
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The median survival time for all patients was 7.4 months with a 1-year 
survival of 28%. Median survival for arm A was 9.4 months, for arm B 
6.8 months. (p=0.6 log rank test). 
Conclusions: the regimen with Carboplatin on day 8 is associated 
with less grade 3-4 neutropenia and thrombocytopenia without loss of 
response rate and is to be preferred.
Table 1.
 overall arm A arm B
Number of patients 69 34 35
Gender 
male 52 25 27
female 17 9 8
Age 
median 61 61 61
range 39-77 41-77 39-74
ECOG Performance 
O 11 6 5
1 58 28 30
Stage of disease    
IIIB 13 6 7
IV 56 28 28
Histology 
squamous 14 8 6
adenocarcinoma 33 17 16
other 22 9 13
Table 2.
Toxicity Arm A Arm B p-value
platelets/ANC gr 3-4 26 (79%) 17 (5O%) O.O14
platelets/ANC gr 4 10 (3O%) 1 (3%) O.OO3
platelets gr 3-4 22 (66.67%) 9 (26.47%) O.OO1
ANC gr 3-4 18 (54.55%) 12 (35.29%) O.113
Response 21% (95% CI, 8-41%) 20% (95% CI, 8-39%) O.89
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Background: A few prospective studies concerning diagnosis and 
treatment of large cell neuroendocrine lung cancer have been pub-
lished, as this tumor seems relatively rare. After the new World Health 
Organisation classiﬁcation of lung tumors in 1999, a result of previous 
or retrospective studies based on the old classiﬁcation seems unexploit-
able. So the GFPC started a prospective study, to establish the efﬁcien-
cy of Cisplatinum /Etoposide chemotherapy patients with LCNE lung 
cancer, diagnosed on the basis of the morphological Travis’s criteria 
and immunohistochemistry. A total of 50 patients was planned.
Methods: Patients with stage IV and stage III B (with neoplasic pleural 
effusion) were selected; treatment is three cycles of Cisplatinum 80mg/
m2 d1 / Etoposide 100mg/m2 d1d2d3 and two more cycles in case of 
Objective Response or Stable disease.
The primary objective was the efﬁciency of this chemotherapy, in 
term of objective response and survival rate. The secondary objectives 
were the improvement of the pathologic diagnosis, with validation of 
the paranuclear granular expression of a large spectrum cytokeratin 
(antibodies). 
Results: In this protocol, 27 patients were included since May 2004. 
The slides of 21 cases were reviewed by a panel of pathologists, mem-
bers of GFPC. Diagnoses were controlled on the basis of the Travis’s 
criteria. 14 cases were conﬁrmed as LCNEC. 4 were excluded on the 
basis of the nuclear criteria or cell size, which made them classiﬁed as 
small-cell carcinomas (SCC). One was excluded, because immunohis-
tochemistry was not available. Two other patients were excluded be-
cause of the misinterpretation of the pathologic report by the clinicians. 
One had been concluded as a SCC, the other as a large cell carcinoma.
After treatment, thirteen patients are assessable for response, a patient 
died eight days after inclusion in the protocol: the chemotherapy was 
well tolerated in eleven cases, the main toxicity was haematological, 
but gastric and renal toxicity appeared in two cases after the ﬁrst cycles 
of chemotherapy and this patients had to used the other treatment . 
In the other cases, after 3 cycles of chemotherapy there was no Com-
plete Response, six Partial Response, three Stable Disease and four 
Progressions and after 5 cycles only four Partial Response, two Stable 
Disease and six Progressions. 
At mars 2007, three patients are alive and eleven patients died. The 
median survival time was 33 weeks.
Conclusion: With twenty seven patients included in this protocol since 
three years and only fourteen patients with LCNEC, it appears that this 
cancer is rarely diagnosed. The main pathological confusion is between 
small-cell and large cell-carcinoma. At last, this chemotherapy seems 
to give good results after three ﬁrst cycles but the effectiveness with 
ﬁve cycles does not seem better than other combinations containing 
platinum. Perhaps is it necessary to propose after three cycles of induc-
tion with cisplatine - etoposide an early modiﬁcation of chemotherapy 
in this rare shape of bronchopulmonary cancer ?
Results will be updated at the meeting
